Back to results
US 11,896,664 B2Granted
Corona virus vaccine formulations
AssigneeNovavax, Inc.
InventorsGale Smith, Michael J. Massare, Jing-Hui Tian
Life of this patent
Estimating the term…
Abstract
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
Claims34
A non-naturally occurring sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (CoV S) glycoprotein, wherein the CoV S glycoprotein comprises two modifications compared to a native S glycoprotein wherein
- (i) the first modification is an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO:
- 7);
- and
- (ii) the second modification is mutation of amino acids 973 and 974 to proline;
- wherein the amino acids are numbered according to SEQ ID NO:
- 2.
3 more elements
Dependencies are inferred from the claim text.